Marc Oliva
@OlivaM_Onc
Followers
714
Following
1K
Media
62
Statuses
942
Medical Oncologist. Head and Neck Cancer and Early Drug Development. Former PMH DDP Fellow.
Barcelona, Espanya
Joined May 2019
El pasado jueves 3/04 desde la @FundacionTTCC lanzamos al mundo la CyC APP 📲, una aplicación móvil creada y diseñada para l@s pacientes con cáncer de cabeza y cuello, sus familias y cuidador@s (1/4) .Más info 👉 o descárgala en App Store y Google Play
1
9
21
RT @anarkogitana: por cada catalan que consume ketamina hay un caballo al que tienen que operar despierto.
0
319
0
RT @JAMAOto: Neoadjuvant therapy, enhanced by anti–PD-1 immunotherapy, shows promise for precision head and neck oncology, but further tria….
0
8
0
RT @NEJM: Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) htt….
0
26
0
RT @JAMAOto: In patients with oral cavity squamous cell carcinoma, adjuvant chemotherapy is beneficial in patients with major extranodal ex….
0
7
0
RT @oncopromesas: Segunda jornada de #PromesasVsSaurios . Avances en #CáncerdeCabezayCuello, #Melanoma, #TumoresCerebrales y #Sarcoma. Part….
0
2
0
This is a HUGE moment for head and neck cancer - most importantly for patients with LA-HNSCC! Thanks to all the patients and families whom so generously participated in this trial. Grateful to the teams at @ICO_oncologia @hbellvitge @idibell_cat for their work in supporting it!.
In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results:
0
1
6
This is a HUGE moment for head and neck cancer - most importantly for patients with LA-HNSCC! Thanks to all the patients and families whom so generously participated in this trial. Grateful to the teams at @ICO_oncologia and @idibell_cat for their work in supporting this. 💪🏼🎊😊.
In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results:
0
1
9
RT @ttccgroup: NIVOPOSTOP Trial Demonstrates DFS Benefit of Adjuvant Nivolumab in High-Risk HNSCC Following Chemoradiotherapy https://t.co/….
dailynews.ascopubs.org
NIVOPOSTOP results show that adding nivolumab to standard adjuvant chemoradiotherapy after surgery significantly improves DFS in patients with high-risk locally advanced head and neck squamous cell...
0
6
0
RT @ttccgroup: Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus–Negative….
ascopubs.org
PURPOSEThe primary aim of this single-arm, phase II trial was to determine the objective response rate (ORR) with palbociclib, a selective CDK4/6 inhibitor, administered before chemoradiotherapy...
0
7
0
Presentando la CyC-APP en representación de la @FundacionTTCC en la Reunión de Primavera @SEORLCCC 💫! Gracias por la invitación y por ayudarnos a hacer difusion 😊 @ttccgroup
0
7
10
RT @lillian_siu: Please beware that there are fake X accounts using my name for alternate therapies - I do not prescribe any such therapies….
0
15
0
RT @ttccgroup: NIVOPOSTOP Trial Demonstrates DFS Benefit of Adjuvant Nivolumab in High-Risk HNSCC Following Chemoradiotherapy https://t.co/….
dailynews.ascopubs.org
NIVOPOSTOP results show that adding nivolumab to standard adjuvant chemoradiotherapy after surgery significantly improves DFS in patients with high-risk locally advanced head and neck squamous cell...
0
4
0
‘Gift of life’: experts hail neck and head cancer breakthrough | Cancer | The Guardian
theguardian.com
Global trial shows immunotherapy drug significantly lowers chance of cancer spreading or returning
0
1
4
RT @_SEOM: ‼️ La infusión de inmunoterapia antes de las 15:00h demuestra mejor supervivencia libre de progresión que la administrada despué….
0
24
0
RT @NEJM: In @NEJMEvidence: In patients with locoregionally advanced nasopharyngeal carcinoma, the 2-year failure-free survival of inductio….
0
6
0
RT @ttccgroup: Enorme orgullo la colaboración de @ttccgroup con GORTEC en el ensayo NIVOPOST OP presentado en la sesión plenaria de #ASCO….
0
12
0
RT @cspramesh: Wonderful to see this out in the @NEJM today. Structured exercise improves survival in colon cancer! Do come to see #ChrisBo….
0
56
0
RT @PaulJiL: 💥Keynote-689 .Favourable DMFS HR 0.71, with half second tumors than SoC.🟠Keynote-412: Novel positive extended DMFS, but OS sti….
0
7
0